Literature DB >> 22191631

Antidiabetic potentials of Momordica charantia: multiple mechanisms behind the effects.

Padmaja Chaturvedi1.   

Abstract

Momordica charantia fruits are used as a vegetable in many countries. From time immemorial, it has also been used for management of diabetes in the Ayurvedic and Chinese systems of medicine. Information regarding the standardization of this vegetable for its usage as an antidiabetic drug is scanty. There are many reports on its effects on glucose and lipid levels in diabetic animals and some in clinical trials. Reports regarding its mechanism of action are limited. So in the present review all the information is considered to produce some concrete findings on the mechanism behind its hypoglycemic and hypolipidemic effects. Studies have shown that M. charantia repairs damaged β-cells, increases insulin levels, and also enhance the sensitivity of insulin. It inhibits the absorption of glucose by inhibiting glucosidase and also suppresses the activity of disaccharidases in the intestine. It stimulates the synthesis and release of thyroid hormones and adiponectin and enhances the activity of AMP-activated protein kinase (AMPK). Effects of M. charantia like transport of glucose in the cells, transport of fatty acids in the mitochondria, modulation of insulin secretion, and elevation of levels of uncoupling proteins in adipose and skeletal muscles are similar to those of AMPK and thyroxine. Therefore it is proposed that effects of M. charantia on carbohydrate and fat metabolism are through thyroxine and AMPK.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22191631     DOI: 10.1089/jmf.2010.0258

Source DB:  PubMed          Journal:  J Med Food        ISSN: 1096-620X            Impact factor:   2.786


  20 in total

1.  Antidiabetic Evaluation of Momordica charantia L Fruit Extracts.

Authors:  S Tahira; F Hussain
Journal:  West Indian Med J       Date:  2014-05-08       Impact factor: 0.171

2.  In vivo hypoglycemic effect of methanolic fruit extract of Momordica charantia L.

Authors:  W Nkambo; N G Anyama; B Onegi
Journal:  Afr Health Sci       Date:  2013-12       Impact factor: 0.927

Review 3.  Novel nutraceutic therapies for the treatment of metabolic syndrome.

Authors:  Esperanza Martínez-Abundis; Miriam Méndez-Del Villar; Karina G Pérez-Rubio; Laura Y Zuñiga; Marisol Cortez-Navarrete; Alejandra Ramírez-Rodriguez; Manuel González-Ortiz
Journal:  World J Diabetes       Date:  2016-04-10

4.  Traditional medicinal plants used for the treatment of diabetes in rural and urban areas of Dhaka, Bangladesh--an ethnobotanical survey.

Authors:  Soeren Ocvirk; Martin Kistler; Shusmita Khan; Shamim Hayder Talukder; Hans Hauner
Journal:  J Ethnobiol Ethnomed       Date:  2013-06-24       Impact factor: 2.733

Review 5.  Beneficial role of bitter melon supplementation in obesity and related complications in metabolic syndrome.

Authors:  Md Ashraful Alam; Riaz Uddin; Nusrat Subhan; Md Mahbubur Rahman; Preeti Jain; Hasan Mahmud Reza
Journal:  J Lipids       Date:  2015-01-12

Review 6.  Traditional Indian medicines used for the management of diabetes mellitus.

Authors:  Syed Ibrahim Rizvi; Neetu Mishra
Journal:  J Diabetes Res       Date:  2013-06-05       Impact factor: 4.011

7.  Role of GLP-1 in the Hypoglycemic Effects of Wild Bitter Gourd.

Authors:  Ting-Ni Huang; Kan-Ni Lu; Yi-Ping Pai; Ching-Jang Huang
Journal:  Evid Based Complement Alternat Med       Date:  2013-03-26       Impact factor: 2.629

Review 8.  Overview of Botanical Status in EU, USA, and Thailand.

Authors:  Weena Jiratchariyakul; Gail B Mahady
Journal:  Evid Based Complement Alternat Med       Date:  2013-10-21       Impact factor: 2.629

Review 9.  Application of Herbal Medicines with Bitter Flavor and Cold Property on Treating Diabetes Mellitus.

Authors:  Hongdong Chen; Jing Guo; Bing Pang; Linhua Zhao; Xiaolin Tong
Journal:  Evid Based Complement Alternat Med       Date:  2015-10-18       Impact factor: 2.629

Review 10.  An Overview of Herbal Products and Secondary Metabolites Used for Management of Type Two Diabetes.

Authors:  Ajda Ota; Nataša P Ulrih
Journal:  Front Pharmacol       Date:  2017-07-06       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.